Our Company

Precision medicine starts with precision diagnostics – this is the core belief of GenomeMe. Since its inception in 2015, GenomeMe has been developing and commercializing novel IVD tools for the detection, characterization and prognosis of cancer in order to make precision medicine more accessible.

Our Awards


awarded with title of 13th Biggest Life Science Company in British Columbia
The Life Sciences industry is booming in Canada. We are honoured to share the title of 13th Biggest Life Science Company in British Columbia with Alectos Therapeutics, BioLytical Laboratories, and Kinexus Bioinformatics Corp in 2017. We are proud to be a part of this fast growing medical innovation community
Molecular Pathology image
GenomeMe was recognized as the 19th Biggest Life Science Company in British Columbia in 2016 by Business in Vancouver Magazine and Life Science BC. Thank you very much for this honor!

Our Certifications


Our newly renovated 9,000 sqf facility located in Vancouver, BC is CMD/CSA ISO 13485:2003 and EN ISO 13485:2012 certified to bring the highest standards of safety and quality to every product and service we offer no matter where in the world you are.

Our Technology

We use the most powerful DNA sequencing and quantification technologies currently on the market to develop products and services to make tomorrow’s healthcare solutions available today.
cfx-01

qPCR Technology

We use qPCR technology to zero in on pathogens and single gene mutations. The qPCR platform is our strategy for HPV detection and the technology behind many of the kits currently in our pipeline for other major infectious diseases such as Brucella bacteria and Norovirus detection.
ngs-01

Next Generation Sequencing

Next Generation Sequencing technology reads billions of DNA strands simultaneously, making it so powerful it can read your entire genetic story in just a few days.
pcr-01

Automated IHC Stainer

Automation is the key ingredient guaranteeing quality, reproducibility and reliability in a fast paced environment. By utilizing this technology for IHC staining we are able to screen, validate, and QC our entire Molecular Pathology portfolio - providing superior quality at a fraction of the cost.